vs
Guardant Health, Inc.（GH）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是Guardant Health, Inc.的1.2倍（$324.4M vs $281.3M），Revolve Group, Inc.净利率更高（5.7% vs -45.7%，领先51.4%），Guardant Health, Inc.同比增速更快（39.4% vs 10.4%），Revolve Group, Inc.自由现金流更多（$-13.3M vs $-54.2M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 9.5%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
GH vs RVLV — 直观对比
营收规模更大
RVLV
是对方的1.2倍
$281.3M
营收增速更快
GH
高出28.9%
10.4%
净利率更高
RVLV
高出51.4%
-45.7%
自由现金流更多
RVLV
多$40.9M
$-54.2M
两年增速更快
GH
近两年复合增速
9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $324.4M |
| 净利润 | $-128.5M | $18.6M |
| 毛利率 | 64.6% | 53.3% |
| 营业利润率 | -43.0% | 6.3% |
| 净利率 | -45.7% | 5.7% |
| 营收同比 | 39.4% | 10.4% |
| 净利润同比 | -15.8% | 50.4% |
| 每股收益（稀释后） | $-1.01 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRVLV
| Q4 25 | $281.3M | $324.4M | ||
| Q3 25 | $265.2M | $295.6M | ||
| Q2 25 | $232.1M | $309.0M | ||
| Q1 25 | $203.5M | $296.7M | ||
| Q4 24 | $201.8M | $293.7M | ||
| Q3 24 | $191.5M | $283.1M | ||
| Q2 24 | $177.2M | $282.5M | ||
| Q1 24 | $168.5M | $270.6M |
净利润GHRVLV
| Q4 25 | $-128.5M | $18.6M | ||
| Q3 25 | $-92.7M | $21.2M | ||
| Q2 25 | $-99.9M | $10.2M | ||
| Q1 25 | $-95.2M | $11.8M | ||
| Q4 24 | $-111.0M | $12.3M | ||
| Q3 24 | $-107.8M | $11.0M | ||
| Q2 24 | $-102.6M | $15.4M | ||
| Q1 24 | $-115.0M | $10.9M |
毛利率GHRVLV
| Q4 25 | 64.6% | 53.3% | ||
| Q3 25 | 64.7% | 54.6% | ||
| Q2 25 | 65.0% | 54.1% | ||
| Q1 25 | 63.3% | 52.0% | ||
| Q4 24 | 61.6% | 52.5% | ||
| Q3 24 | 61.1% | 51.2% | ||
| Q2 24 | 59.1% | 54.0% | ||
| Q1 24 | 61.2% | 52.3% |
营业利润率GHRVLV
| Q4 25 | -43.0% | 6.3% | ||
| Q3 25 | -37.3% | 7.1% | ||
| Q2 25 | -45.9% | 5.8% | ||
| Q1 25 | -54.6% | 5.0% | ||
| Q4 24 | -62.4% | 3.9% | ||
| Q3 24 | -61.3% | 5.0% | ||
| Q2 24 | -56.8% | 5.8% | ||
| Q1 24 | -59.2% | 3.4% |
净利率GHRVLV
| Q4 25 | -45.7% | 5.7% | ||
| Q3 25 | -35.0% | 7.2% | ||
| Q2 25 | -43.0% | 3.3% | ||
| Q1 25 | -46.8% | 4.0% | ||
| Q4 24 | -55.0% | 4.2% | ||
| Q3 24 | -56.3% | 3.9% | ||
| Q2 24 | -57.9% | 5.4% | ||
| Q1 24 | -68.2% | 4.0% |
每股收益（稀释后）GHRVLV
| Q4 25 | $-1.01 | $0.27 | ||
| Q3 25 | $-0.74 | $0.29 | ||
| Q2 25 | $-0.80 | $0.14 | ||
| Q1 25 | $-0.77 | $0.16 | ||
| Q4 24 | $-0.90 | $0.18 | ||
| Q3 24 | $-0.88 | $0.15 | ||
| Q2 24 | $-0.84 | $0.21 | ||
| Q1 24 | $-0.94 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $292.3M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $512.5M |
| 总资产 | $2.0B | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRVLV
| Q4 25 | $378.2M | $292.3M | ||
| Q3 25 | $580.0M | $315.4M | ||
| Q2 25 | $629.1M | $310.7M | ||
| Q1 25 | $698.6M | $300.8M | ||
| Q4 24 | $525.5M | $256.6M | ||
| Q3 24 | $585.0M | $252.8M | ||
| Q2 24 | $933.7M | $244.7M | ||
| Q1 24 | $1.0B | $273.4M |
总债务GHRVLV
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHRVLV
| Q4 25 | $-99.3M | $512.5M | ||
| Q3 25 | $-354.5M | $490.2M | ||
| Q2 25 | $-305.5M | $468.6M | ||
| Q1 25 | $-250.8M | $453.4M | ||
| Q4 24 | $-139.6M | $437.8M | ||
| Q3 24 | $-60.1M | $420.8M | ||
| Q2 24 | $-1.6M | $405.8M | ||
| Q1 24 | $68.3M | $389.9M |
总资产GHRVLV
| Q4 25 | $2.0B | $765.0M | ||
| Q3 25 | $1.3B | $751.3M | ||
| Q2 25 | $1.3B | $722.9M | ||
| Q1 25 | $1.3B | $713.9M | ||
| Q4 24 | $1.5B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.6B | $657.8M | ||
| Q1 24 | $1.7B | $650.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $-13.3M |
| 自由现金流率自由现金流/营收 | -19.3% | -4.1% |
| 资本支出强度资本支出/营收 | 9.9% | 1.0% |
| 现金转化率经营现金流/净利润 | — | -0.55× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $48.0M |
8季度趋势，按日历期对齐
经营现金流GHRVLV
| Q4 25 | $-26.4M | $-10.2M | ||
| Q3 25 | $-35.4M | $11.8M | ||
| Q2 25 | $-60.3M | $12.6M | ||
| Q1 25 | $-62.7M | $45.1M | ||
| Q4 24 | $-64.5M | $3.9M | ||
| Q3 24 | $-51.1M | $9.1M | ||
| Q2 24 | $-94.0M | $-24.7M | ||
| Q1 24 | $-30.3M | $38.4M |
自由现金流GHRVLV
| Q4 25 | $-54.2M | $-13.3M | ||
| Q3 25 | $-45.8M | $7.5M | ||
| Q2 25 | $-65.9M | $10.4M | ||
| Q1 25 | $-67.1M | $43.4M | ||
| Q4 24 | $-83.4M | $2.1M | ||
| Q3 24 | $-55.3M | $8.0M | ||
| Q2 24 | $-99.1M | $-25.7M | ||
| Q1 24 | $-37.2M | $36.7M |
自由现金流率GHRVLV
| Q4 25 | -19.3% | -4.1% | ||
| Q3 25 | -17.3% | 2.5% | ||
| Q2 25 | -28.4% | 3.4% | ||
| Q1 25 | -33.0% | 14.6% | ||
| Q4 24 | -41.3% | 0.7% | ||
| Q3 24 | -28.9% | 2.8% | ||
| Q2 24 | -55.9% | -9.1% | ||
| Q1 24 | -22.1% | 13.5% |
资本支出强度GHRVLV
| Q4 25 | 9.9% | 1.0% | ||
| Q3 25 | 3.9% | 1.5% | ||
| Q2 25 | 2.4% | 0.7% | ||
| Q1 25 | 2.2% | 0.6% | ||
| Q4 24 | 9.4% | 0.6% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 2.9% | 0.4% | ||
| Q1 24 | 4.1% | 0.6% |
现金转化率GHRVLV
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | — | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
